Equities

Dextech Medical AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Dextech Medical AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)11.50
  • Today's Change-0.300 / -2.54%
  • Shares traded3.38k
  • 1 Year change+173.81%
  • Beta0.7374
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Dextech Medical AB is a Sweden-based research company specialized in urologic oncology. It is focused on prostate cancer, but also other cancers and non-malignant diseases. It develops drug canditates based on modified carbohydrate molecule combined with active substances. The Company has a patented technology platform, GuaDex, and three drug candidates with patents or patent applications. The portfolio includes: OsteoDex, for treatment of bone metastases in castration resistant prostate cancer (CRPC); SomaDex, based on endogenous hormone, somatostatin, and aimed at treatment of acromegaly, neuroendocrine tumors and palliative treatment of CRPC; and CatDex, for instillation treatment of bladder cancer.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-4.96m
  • Incorporated2004
  • Employees1.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Alzinova AB205.00k-26.88m121.18m5.00--0.5924--591.13-0.2846-0.28460.00221.230.0015--0.325441,000.00-19.42-12.21-20.69-12.85-5,834.15---13,114.15-21,390.81---1,794.800.0062---88.89---24.71--19.48--
SoftOx Solutions AS12.68m-2.80m131.84m5.00--1.30175.3910.39-0.001-0.0010.00650.04450.123--30.132,717,798.00-2.72-50.91-3.22-67.07-----22.07-644.921.16-3.920.1212--13.3814.06-8.86------
ViroGates A/S7.14m-17.53m154.36m7.00--32.06--21.63-1.63-1.630.66090.36650.35680.97774.41504,300.00-87.63-54.92-131.36-63.1547.3372.98-245.63-215.481.58-16.130.6277---12.276.45-18.59------
SenzaGen AB57.88m-16.18m164.04m37.00--2.21--2.83-0.5483-0.54831.962.520.55775.476.631,702,294.00-15.59-20.91-18.89-25.1765.0967.10-27.95-71.432.73--0.0707--15.6984.1619.22---1.18--
NextCell Pharma AB10.94m-35.14m167.09m24.00--2.52--15.28-0.4414-0.44140.1330.5960.138451.234.68---44.48-34.95-49.25-37.53-155.37-266.34-321.31-427.089.92------2.5625.1316.25--36.88--
Oncoinvent ASA5.04m-100.41m179.59m7.00--0.3911--35.60-176.33-176.338.86109.850.0354--0.4134360,333.30-70.49-68.76-88.81-82.93-----1,990.44-40,397.77----0.00--139.55-37.5126.85------
Circio Holding ASA0.00-8.58m194.45m9.007.98------0.13480.13480.00-0.08360.00----0.00-93.87-47.84---58.78-------6,460.26---------100.00--150.93--7.12--
Sprint Bioscience AB49.53m-25.65m197.31m29.00--32.54--3.98-0.2986-0.29860.58320.05751.47--6.021,303,316.00-76.04-60.40-262.43-100.7261.9457.87-51.79-87.25---36.010.00--30.0214.37-4,072.83--69.39--
Initiator Pharma A/S0.00-16.42m203.70m2.00--4.44-----0.2727-0.27270.000.67040.00----0.00-43.00-67.58-46.15-73.43------------0.0619------53.32------
Dextech Medical AB0.00-4.96m212.59m1.00--8.89-----0.2684-0.26840.001.290.00----0.00-18.58-19.36-18.94-19.80------------0.00-------2.96--40.14--
Xbrane Biopharma AB209.08m-72.86m218.38m26.00--0.372--1.04-5.168.9914.5728.490.27130.28995.003,216,539.00-9.46-37.48-15.30-65.1371.25---34.85-233.691.71-1.490.00---16.76--17.70--113.17--
AlzeCure Pharma AB0.00-39.20m226.96m11.00--4.48-----0.4047-0.40470.000.44090.00----0.00-71.83-73.70-88.08-83.65------------0.053------5.20---38.94--
Klaria Pharma Holding AB (publ)11.23m-58.70m233.68m4.00--51.41--20.80-0.4069-0.30930.06990.01850.201--5.342,808,250.00-105.02-48.20-649.38-74.06-----522.58-1,522.52---2.470.1195---73.41-11.85-33.44------
Promimic AB45.57m-12.13m238.99m18.00--3.92--5.24-0.6388-0.63882.403.230.603-3.563.622,398,421.00-16.05-20.50-18.57-24.44105.07104.49-26.62-59.753.52--0.00--18.6350.25-36.09------
Xintela AB2.96m-42.28m244.60m13.00------82.72-0.0665-0.06650.0046-0.03960.3486--6.47227,461.50-498.42-194.17---651.77100.00---1,429.86-6,272.93---16.40----5,303.85156.4527.54------
Bio-Works Technologies AB41.41m-29.78m264.23m29.00--7.20--6.38-0.50-0.500.58780.37380.69310.98666.451,380,200.00-49.84-50.49-67.92-61.3972.6870.42-71.91-140.951.65--0.00---41.9935.5134.25---48.46--
Data as of Feb 10 2026. Currency figures normalised to Dextech Medical AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.